-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DXuTTYZHMqr7cG/t9jdS/n0x326zlcvGIK+j1K5CGalpqJU4PG9YB37mBn5ptU7U Fc69W5qy/s4OTzV5KcgS8A== 0000891020-96-000907.txt : 19960813 0000891020-96-000907.hdr.sgml : 19960813 ACCESSION NUMBER: 0000891020-96-000907 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19960630 FILED AS OF DATE: 19960812 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARGETED GENETICS CORP /WA/ CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 96608985 BUSINESS ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 2066237612 MAIL ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 10-Q 1 TARGETED GENETICS CORPORATION FORM 10-Q 1 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [ x ] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 1996 or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________ to __________ Commission File Number: 0-23930 TARGETED GENETICS CORPORATION (Exact name of registrant as specified in its charter) WASHINGTON 91-1549568 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 1100 OLIVE WAY, SUITE 100, SEATTLE, WASHINGTON 98101 (Address of principal executive offices) (Zip Code) (206) 623-7612 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ x ] No [ ] Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. COMMON STOCK, $.01 PAR VALUE 20,115,668 (Class) (Outstanding at July 29, 1996)
2 TARGETED GENETICS CORPORATION Quarterly Report on Form 10-Q June 30, 1996 TABLE OF CONTENTS
Page No. -------- PART I FINANCIAL INFORMATION Item 1. Financial Statements a) Condensed Consolidated Balance Sheets - June 30, 1996 and December 31, 1995 3 b) Condensed Consolidated Statements of Operations - for the three and six months ended June 30, 1996 and 1995 4 c) Condensed Consolidated Statements of Cash Flows - for the three and six months ended June 30, 1996 and 1995 5 d) Notes to Condensed Consolidated Financial Statements 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 8 PART II OTHER INFORMATION Item 1. Legal Proceedings * Item 2. Changes in Securities * Item 3. Defaults Upon Senior Securities * Item 4. Submission of Matters to a Vote of Security Holders 11 Item 5. Other Information * Item 6. Exhibits and Reports on Form 8-K 12 SIGNATURES 13
* No information is provided due to inapplicability of the item. 2 3 PART I FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS TARGETED GENETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, December 31, 1996 1995 ---- ---- ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 7,238,531 $ 2,154,814 Securities available for sale 17,193,038 12,287,748 Deposits, prepaid expenses and other 529,888 196,150 ------------ ------------ Total current assets 24,961,457 14,638,712 Property, plant and equipment, net 5,143,386 4,959,502 Other assets 400,730 362,246 ------------ ------------ $ 30,505,573 $ 19,960,460 ============ ============ LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,489,743 $ 564,403 Accrued payroll and other liabilities 279,595 336,713 Current portion of long-term obligations 1,053,308 881,210 ------------ ------------ Total current liabilities 3,822,646 1,782,326 Long-term obligations 2,428,852 2,405,298 Shareholders' equity: Preferred stock -- -- Common stock (19,540,848 and 12,317,183 shares outstanding at June 30, 1996 and December 31, 1995, respectively) 71,117,882 43,295,436 Deficit accumulated during development stage (46,863,807) (27,522,600) ------------ ------------ Total shareholders' equity 24,254,075 15,772,836 ------------ ------------ $ 30,505,573 $ 19,960,460 ============ ============
See accompanying notes. 3 4 ITEM 1. FINANCIAL STATEMENTS (CONTINUED) TARGETED GENETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Period from March 9, 1989 (date of inception) Three months ended Six months ended through June 30, June 30, June 30, ----------------------------- ----------------------------- ------------- 1996 1995 1996 1995 1996 ----------- ----------- ------------ ------------ ------------- Investment and other income $ 230,277 $ 179,459 $ 413,813 $ 311,996 $ 2,665,720 Expenses: Research and development 2,431,607 1,956,580 4,797,639 3,934,896 27,568,759 In-process research and development 13,517,911 -- 13,517,911 -- 13,517,911 General and administrative 554,111 534,121 1,170,973 1,235,134 7,745,693 Interest 103,125 78,464 195,506 153,304 690,492 ----------- ----------- ----------- ----------- ------------ Total expenses 16,606,754 2,569,165 19,682,029 5,323,334 49,522,855 ------------ ----------- ------------ ----------- ------------ Net loss $(16,376,477) $(2,389,706) $(19,268,216) $(5,011,338) $(46,857,135) ============ =========== ============ =========== ============ Net loss per share $ (1.26) $ (0.27) $ (1.52) $ (0.56) ============ =========== ============ =========== Shares used in computation of net loss per share 13,031,247 8,974,194 12,690,294 8,970,614 ============ =========== ============ ===========
See accompanying notes. 4 5 ITEM 1. FINANCIAL STATEMENTS (CONTINUED) TARGETED GENETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
Period from March 9, 1989 (date of inception) Three months ended Six months ended through June 30, June 30, June 30, ---------------------------- ---------------------------- 1996 1995 1996 1995 1996 ------------ ------------ ------------ ------------ ------------ Net cash used in operating activities $ (2,956,376) $ (2,297,800) $ (5,558,934) $ (4,736,131) $(29,527,199) Investing activities: Purchases of property, plant and equipment (472,111) (234,736) (991,593) (507,500) (8,162,190) Purchases of securities available for sale (10,990,684) (761,090) (12,504,553) (2,733,976) (67,595,075) Sales of securities available for sale 4,353,409 3,286,462 7,720,112 6,124,761 50,672,132 Net cash acquired in RGene acquisition 2,977,185 -- 2,977,185 -- 2,977,185 Increase in other assets -- (32,500) -- (62,500) (574,179) ------------ ------------ ------------ ------------ ------------ Net cash provided by (used in) investing activities (4,132,201) 2,258,136 (2,798,849) 2,820,785 (22,682,127) Financing activities: Advances from Immunex -- -- -- -- 2,807,316 Net proceeds from sale of capital stock 12,948,559 440 13,245,848 8,735 53,667,968 Proceeds from equipment financing 92,933 -- 646,996 237,459 4,493,290 Payments under capital leases and installment loans (240,457) (155,426) (451,344) (296,252) (1,520,717) ------------ ------------ ------------ ------------ ------------ Net cash provided by financing activities 12,801,035 (154,986) 13,441,500 (50,058) 59,447,857 ------------ ------------ ------------ ------------ ------------ Net increase (decrease) in cash and cash equivalents 5,712,458 (194,650) 5,083,717 (1,965,404) 7,238,531 Cash and cash equivalents, beginning of period 1,526,073 536,225 2,154,814 2,306,979 -- ------------ ------------ ------------ ------------ ------------ Cash and cash equivalents, end of period $ 7,238,531 $ 341,575 $ 7,238,531 $ 341,575 $ 7,238,531 ============ ============ ============ ============ ============
See accompanying notes. 5 6 ITEM 1. FINANCIAL STATEMENTS (CONTINUED) TARGETED GENETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1. Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Targeted Genetics Corporation (the "Company"), without audit, according to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (which consist solely of normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the three and six months ended June 30, 1996 are not necessarily indicative of the results to be expected for the full year. Note 2. Acquisition of RGene Therapeutics, Inc. On June 19, 1996, the Company completed its acquisition of RGene Therapeutics, Inc. ("RGene"), a privately held gene therapy company. The Company issued 3,636,364 shares of common stock in exchange for all the outstanding capital stock of RGene at approximately $4.08 per share. The shares are currently unregistered but the Company has agreed to register 50 percent of the shares issued in the merger one year from the date of the closing. The transaction was accounted for as a purchase and the consideration issued by the Company was allocated to tangible assets acquired based on their estimated fair values on the acquisition date. The aggregate purchase price of $17,822,000 consisted of (in thousands): Market value of capital stock $14,854 Acquisition costs and expenses 650 Liabilities assumed 2,318 ------- Total purchase price $17,822
6 7 ITEM 1. FINANCIAL STATEMENTS (CONTINUED) Note 2. Acquisition of RGene Therapeutics, Inc. (continued) The aggregate purchase price exceeded the fair value of RGene's tangible assets by $13,518,000. This amount was allocated to acquired in-process research and development and written off to operations in the second quarter of 1996. The allocation of the aggregate purchase price was as follows (in thousands): Current assets $ 4,304 In-process technology 13,518 -------- $ 17,822
The following summarized unaudited pro forma results of operations for the six-month periods ended June 30, 1996 and 1995, respectively, assume the acquisition occurred as of the beginning of the respective periods (dollars in thousands, except for per share amounts): 1996 1995 ---- ---- Revenue $ 5,455 $ 357 Net loss (4,983) (6,349) Net loss per share (0.31) (0.50)
The pro forma results presented above do not include certain one-time charges related to the acquisition of RGene. The Company may issue up to $5 million in additional common stock to RGene's former stockholders based on the achievement of certain clinical and business-related milestones prior to December 31, 1998. Note 3. Subsequent Events On July 11, 1996, the Company's underwriters exercised their over-allotment option to purchase an additional 525,000 shares of stock at the offering price of $4.00 per share. The option was granted on June 20, 1996, in connection with the Company's public offering of 3.5 million shares of common stock. 7 8 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Financial Condition The Company had cash, cash equivalents and securities available for sale totaling $24.4 million as of June 30, 1996, compared to $14.4 million at December 31, 1995. The increase was primarily attributable to net proceeds of $12.9 million from the Company's recent public offering and $3.0 million from the acquisition of RGene Therapeutics, Inc. ("RGene"), offset by the use of $5.6 million to fund its operations during the first six months of 1996. The Company is a development stage company conducting gene and cell therapy research and development. Income earned from investments has been its only significant source of revenue. Gene and cell therapy products are subject to the risks of failure inherent in the development of products based on innovative technologies. Although the Company's technology appears promising, it is unknown whether any commercially viable products will result from the research and development. It is not anticipated that the Company will have any product-related revenues for a number of years. Accordingly, the Company expects to incur substantial additional losses over the next several years and to use its capital resources to fund preclinical and clinical research programs, development of manufacturing capabilities and the preparation for commercialization of its products under development. On June 19, 1996, the Company completed a merger with RGene, a private biotechnology firm located in The Woodlands, Texas. As a result of this transaction, Targeted Genetics acquired proprietary non-viral gene delivery technology that complements the viral technologies the Company currently has under development, a potential gene therapy product for the treatment of cancer and key consulting and collaborative relationships with other leading scientists in the gene therapy field. Under terms of the merger agreement, the Company acquired all the outstanding shares of RGene stock in exchange for approximately 3.64 million unregistered shares of the Company's common stock. The transaction was accounted for using the purchase method of accounting and the consideration issued by the Company was allocated to the tangible and intangible assets acquired. The Company acquired $2,977,000 of cash and cash equivalents in the transaction, $1,425,000 of which will be used to satisfy liabilities assumed from RGene. The Company recently raised $14 million through the completion of a public offering of 3.5 million shares of common stock at $4.00 per share. The net proceeds of the offering will be used to fund continuing operations in research and development, clinical testing and for capital expenditures. The Company currently estimates that, at its planned rate of spending, adjusted to reflect the increased expenses expected to result from the RGene merger, its existing cash, cash equivalents and securities available for 8 9 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED) Financial Condition (continued) sale will be sufficient to meet its capital requirements until at least late 1997. Such estimates include the impact of future milestone payments potentially receivable under RGene collaborative agreements assumed by the Company in the merger. There can be no assurance that the underlying assumed levels of revenue and expense will prove to be accurate. Substantial additional funds will be needed to continue the development and commercialization of the Company's products. Accordingly, the Company is seeking to establish additional collaborative agreements with corporate partners that would provide research and development funding and equity investment. The Company also may seek to raise additional equity capital whenever conditions in the financial markets allow it to do so. There can be no assurance, however, that adequate funds will be available when needed or will be available on terms favorable to the Company. The above forward-looking statement regarding the Company's future capital requirements is subject to certain risks and uncertainties that could cause the actual results to differ materially from those projected. The Company's future cash requirements will depend on many factors, including the successful consolidation of RGene with the Company; continued scientific progress in its research and development programs; the results of research and development, preclinical studies and clinical trials; acquisition of products or technology, if any; relationships with corporate collaborators; competing technological and market developments; the time and costs involved in obtaining regulatory approvals; the costs involved in filing, prosecuting and enforcing patent claims; the time and costs of manufacturing scale-up and commercialization activities; and other factors. Readers are cautioned not to place undue reliance on this forward-looking statement, which speaks only as of the date of this report. The Company undertakes no obligation to publicly release the results of any revisions to this forward-looking statement that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events. Results of Operations Over the past several years, the Company's net loss has grown, consistent with the growth in the Company's scope and size of operations. In the near term, the Company plans additional moderate growth in employee headcount necessary to address increasing requirements in the areas of manufacturing, quality control, clinical and regulatory affairs. Assuming capital is available to finance such growth, the Company's operating expenses will continue to increase as a result. At least until such time as the Company enters into an arrangement providing research and development funding, the net loss will continue to increase as well. 9 10 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED) Results of Operations (continued) For the three and six months ended June 30, 1996, investment and other income increased to $230,000 and $414,000 compared to $179,000 and $312,000 during the three and six months ended June 30, 1995. The increase was attributable to a higher average cash balance for investment and higher rates of return on those balances compared to the same period in 1995. Research and development expenses were $2,432,000 and $4,798,000 for the three and six months ended June 30, 1996, and $1,957,000 and $3,935,000 for the three and six months ended June 30, 1995. Factors that contributed to the increase in both current year periods compared to the same periods in 1995 were: an increase in the level of expenses for development, manufacturing, quality control, and regulatory activities supporting the Company's clinical trials; additional employees and related expenses in preclinical immunology; and increased employee benefits costs. A one-time expense resulting from the acquisition of RGene was charged against income in the second quarter of 1996. The RGene purchase price exceeded the fair value of tangible assets acquired by $13,518,000. This amount was allocated to RGene's existing in-process technology and was written off in the current period to in-process research and development expense. General and administrative expenses were $554,000 and $1,171,000 for the three and six months ended June 30, 1996, and $534,000 and $1,235,000 for the three and six months ended June 30, 1995. The Company experienced a moderate increase in the expenses for the three- and six-month periods consistent with the Company's growth. The impact of a one-time expense of $196,000 related to certain corporate development activities is reflected in the six-month period ended June 30, 1995. Interest expense was $103,000 and $196,000 for the three and six months ended June 30, 1996, and $78,000 and $153,000 for the three and six months ended June 30, 1995. The increases were attributable to the additional equipment leases entered into by the Company. 10 11 PART II OTHER INFORMATION ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS An annual meeting of the Company's shareholders ("Shareholders") was held on Thursday, May 2, 1996 (the "Annual Meeting"). Of the 12,397,484 shares outstanding as of the record date, March 8, 1996, 10,572,222 shares, or 85.3% of the total shares eligible to vote at the Annual Meeting, were represented in person or by proxy. Two matters were submitted to a vote of the Shareholders at the Annual Meeting. First, an amendment to the 1992 Stock Option Plan providing for an increase in the number of shares available for grant from 1,400,000 to 2,000,000 was approved by 92.3% of the votes represented at the meeting. Second, Jeremy Curnock Cook, Stephen A. Duzan and James D. Grant were elected as Directors of the Company by 95.9% of the shares represented at the meeting. A special meeting of Shareholders was held on Wednesday, June 19, 1996 (the "Special Meeting"). Of the 12,398,284 shares outstanding as of the record date, April 23, 1996, 8,791,837 shares, or 70.9% of the total shares eligible to vote at the Special Meeting, were represented in person or by proxy. One matter was submitted to a vote of the Shareholders at the Special Meeting. The Shareholders were asked to approve the issuance of 3,636,364 shares of common stock plus additional shares, upon the achievement of certain milestones, having a value of up to $5 million under the terms of a merger agreement, pursuant to which the Company would acquire all of the outstanding shares of RGene Therapeutics, Inc. This matter was approved by 99.8% of the votes represented at the meeting. No other matters were submitted to a vote of the Shareholders. 11 12 PART II OTHER INFORMATION ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K (a) The following exhibit is filed as part of this report. Exhibit No. Description ----------- ----------- 10.1 Amendment to the First Amended and Restated License Agreement, between The University of Tennessee Research Corporation and RGene Therapeutics, Inc., dated as of June 19, 1996. 27 Financial Data Schedule. (b) A Current Report on Form 8-K dated April 16, 1996 was filed with the Securities and Exchange Commission reporting that Targeted Genetics Corporation had entered into a merger agreement with RGene Therapeutics, Inc. 12 13 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TARGETED GENETICS CORPORATION ----------------------------------------------- (Registrant) Date August 12, 1996 /s/ H. STEWART PARKER ------------------------------------------------- H. Stewart Parker, Chief Executive Officer (Principal Executive Officer) Date August 12, 1996 /s/ JAMES A. JOHNSON -------------------------------------------------- James A. Johnson, Vice President, Finance (Principal Financial and Accounting Officer) 13 EX-10.1 2 AMEND. TO THE AMEND AND RESTATED LICENSE AGREEMENT 1 EXHIBIT 10.1 TO FORM 10-Q "[*]" = confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 2 AMENDMENT TO THE FIRST AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION AND RGENE THERAPEUTICS, INC. To All Those Concerned: This is an Amendment to the First Amended And Restated License Agreement between The University Of Tennessee Research Corporation and RGene Therapeutics, Inc. having an effective date of October 12, 1995 (the "Agreement"). UTRC and RGENE agree to amend the Agreement as of June 19, 1996, effective as of October 12, 1995, as stated below. Section 2.7 is hereby amended to recite: 2.7 It is specifically acknowledged that i) UTRC licensed certain Technology to Argus Pharmaceuticals, Inc. ("Argus") through an agreement effective as of November 1, 1993; ii) that effective October 12, 1995, Argus Pharmaceuticals, Inc. changed its name to Aronex Pharmaceuticals, Inc. ("Aronex"); and iii) that Aronex and UTRC amended the November 1, 1993 Agreement though a First Amended and Restated License Agreement executed on December 6 and 8, 1995. It is also specifically acknowledged that Aronex, then Argus, granted RGENE a sublicense to its UTRC Technology through the Sublicense Agreement effective April 6, 1994. Section 4.1 is hereby amended to recite: 4.1 As consideration for the license hereby granted to RGENE, including a license to the Technology licensed to Aronex by UTRC and sublicensed to RGENE as set forth above in Section 2.7, and which consideration shall be accepted by UTRC as including payment in full satisfaction of any consideration due UTRC by Aronex: Section 4.1 C and 4.1 C (1) of the Agreement are hereby amended to recite: 3 C. RGENE shall pay to UTRC Running Royalties in an amount equal to [*] of all Net Sales by RGENE and Affiliate Sublicensees of Licensed Products that are covered by a claim of an issued and unexpired patent included within Licensed Patent Rights in the place of manufacture, use, or sale, provided: (1) If, in order to manufacture or sell any Licensed Product covered by this Article 4.1C, RGENE or any Affiliate Sublicensees are required to obtain from one or more third parties who are not Affiliates other royalty bearing license(s) for additional drug delivery technology, the Running Royalty rate payable hereunder on Net Sales of that Licensed Product shall be reduced by [*] for each such license actually entered into by RGENE or an Affiliate Sublicensee, provided that in no event shall the Running Royalty rate be less than [*] of Net Sales and further provided that the reduced Running Royalty rate shall apply only to sales of that Licensed Product on which RGENE or an Affiliate Sublicensee actually owes and pays a royalty to a non-Affiliate third party. Section 4.1 D and 4.1 D (1) of the Agreement are hereby amended to recite: D. RGENE shall pay UTRC Running Royalties in an amount equal to [*] of all Net Sales of Licensed Products that are not covered by the provisions of Article 4.1C above by RGENE and Affiliate Sublicensees during each calendar quarter during the term of this Agreement, provided: (1) If, in order to manufacture or sell any Licensed Product covered by this Article 4.1D, RGENE or any Affiliate Sublicensees are required to obtain from one or more non-Affiliate third parties other royalty bearing license(s) for additional drug delivery technology, the Running Royalty rate payable hereunder on Net Sales of that Licensed Product shall be reduced by [*] for each such license actually entered into by RGENE or an Affiliate Sublicensee, provided that in no event shall the Running Royalty rate be less than [*] of Net Sales and further provided that the reduced Running Royalty rate shall apply only to sales of that Licensed Product on which RGENE or an Affiliate Sublicensee actually owes and pays a royalty to a non-Affiliate third party. Section 4.1 E of the Agreement is hereby amended to recite: - --------------------------------- [*] Confidential Treatment Requested -2- 4 E. RGENE shall pay to UTRC Sublicense Fees and Royalties as follows: (1) Sublicense Fees For each sublicense and option to sublicense granted hereunder, RGENE shall pay UTRC [*] of the net compensation received by RGENE. The term "net compensation" as used herein shall mean the gross compensation received by RGENE under such sublicenses less (a) running royalties and (b) any payment received by RGENE from the sublicensee for (i) purchase of Licensed Product from RGENE (the amount excluded hereunder not to exceed RGENE's direct out-of-pocket cost of manufacturing and shipping such Licensed Product) and (ii) services provided by RGENE to the sublicensee, directly or indirectly (the amount deducted hereunder not to exceed RGENE's direct out-of-pocket cost of providing such services). (2) Sublicense Royalties RGENE shall pay UTRC a Sublicense Royalty equal to [*] of the running royalties received from RGENE's sublicensees, RGENE shall be entitled to deduct from such Sublicense Royalty an amount equal to running royalties actually paid by RGENE to any non-Affiliate licensor (other than UTRC) for the Licensed Product that generated the Sublicense Royalty, provided that in no event shall the Sublicense Royalty paid to UTRC be so reduced by more than [*] and further provided that UTRC shall receive as a Sublicense Royalty not less than [*] nor more than [*] of the sublicensee's Net Sales of Licensed Product. (3) Notwithstanding the foregoing, UTRC will receive [*] of any compensation received by RGENE as a result of the License Agreement between RGENE and Pasteur Merieux Serums & Vaccins S.A. dated December 15, 1995, excluding sales of Licensed Product by RGENE to Pasteur Merieux Serums & Vaccins S.A. or its sublicensee (the amount excluded hereunder not to exceed RGENE's direct out-of-pocket cost of manufacturing and shipping such Licensed Product). Section 8.1 shall be amended to recite: - --------------------------------- [*] Confidential Treatment Requested -3- 5 8.1 In the event that UTRC, The University of Tennessee, M McMaster, any of their directors, officers, or employees, or any individual named as an inventor of Licensed Patent Rights (hereinafter) "Indemnified Party" is charged with infringement of a patent by a third party or is made a party in any lawsuit (including but not limited to products liability actions) as a result of the manufacture, use, or sale of any Licensed Product under this Agreement or as a result of any obligation or activity of RGENE or its sublicensees under the Agreement or any sublicense, RGENE shall: A. defend or settle, at RGENE's expense, any such claim of infringement or lawsuit; B. assume all costs, expenses, damages and other obligations for payments incurred as a consequence of such charges of infringement or lawsuit; and C. indemnify and hold such Indemnified Party harmless for any and all damages, losses, liability, and costs resulting from such charge of infringement or lawsuit. Section 8.6 shall be amended to recite: 8.6. RGENE agrees to carry such liability insurance as would reasonably be expected of a company of RGENE's size and activities operating in the pharmaceutical industry. At all times during this the term of this Agreement, UTRC and McMaster shall be listed as an additional named insured on such liability insurance policy(ies). RGENE agrees to provide written evidence of such insurance upon request by UTRC or McMaster. After 15.11, insert: 16. ARBITRATION Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction, or other equitable relief to preserve the status quo or to prevent irreparable harm, or to enforce the provisions of this Article 16, in the event any dispute arises between any of the parties to this Agreement as to the validity, construction, enforceability or performance of the Agreement or any of its provisions, such dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association with a panel of three (3) arbitrators. The Federal rules of discovery shall apply to the arbitration. The decision and judgment of the arbitrators may be entered and enforced in any court having jurisdiction thereof. 6 IN WITNESS WHEREOF, the parties hereto have caused the Agreement to have been amended and to be duly executed as of June 18, 1996 with an effective date of October 12, 1995. RGENE THERAPEUTICS, INC. THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION By: /s/ Martin Lindenberg By: /s/ Ann J. Roberson ---------------------------------- ------------------- Name: Martin Lindenberg Name: Ann J. Roberson Title: President and CEO Title: President Date: June 19, 1996 Date: June 19, 1996 ------------------------------- ------------- Approved by MCMASTER UNIVERSITY By: /s/ Ronald F. Childs --------------------------- Name: Ronald F. Childs ------------------------- Title: Vice President, Research ------------------------- Date: June 19, 1996 ------------------------- -2- EX-27 3 TARGETED GENETICS CORP. FINANCIAL DATA SCHEDULE
5 6-MOS DEC-31-1996 JAN-01-1996 JUN-30-1996 7,238,531 17,193,038 0 0 0 24,961,457 8,886,819 3,743,433 30,505,573 3,822,646 0 0 0 71,117,882 (46,863,807) 30,505,573 0 0 0 0 4,797,639 0 413,813 (19,268,216) 0 (19,268,216) 0 0 0 (19,268,216) (1.52) (1.52)
-----END PRIVACY-ENHANCED MESSAGE-----